TAK: 6-K company filing

6-K 1 form6k-2_102926.htm 6-K Document Table of Contents FORM 6-K ________________________________________ U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of October 2026 ________________________________________ TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) ________________________________________ 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of principal executive offices) ________________________________________ Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Table of Contents Information furnished on this form: Pursuant to the Financial Instruments and Exchange Act of Japan, Takeda Pharmaceutical Company Limited filed its Semi-annual Securities Report for The Six-month Period with the Director of the Kanto Local Finance Bureau in Japan on October 29, 2026. An English translation of such report is included as an exhibit hereto. EXHIBIT Exhibit Number 1. (English Translation) Semi-annual Securities Report For The Six -month Period Ended September 30, 2026 99.1 Financial Appendix (incorporated by reference to Exhibit 99.1 to Form 6-K of the Registrant, filed on October 29 , 202 6 ) Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchang